Genetic Analysis of Drug Metabolizing Phase-I Enzymes CYP3A4 in Tibetan Populations

Overview

Journal J Genet

Specialty Genetics

Date 2017 Jul 5

PMID 28674221

Citations 1

Authors

Lijun Liu

Yu Chang

Shuli Du

Xugang Shi

Hua Yang

Longli Kang

Tianbo Jin

Dongya Yuan

Yongjun He

Affiliations

Soon will be listed here.

Abstract

The enzymatic activity of CYP3A4 results in broad interindividual variability in response to certain pharmacotherapies. The present study aimed to screen Tibetan volunteers for CYP3A4 genetic polymorphisms. Previous research has focussed on Han Chinese patients, while little is known about the genetic variation of CYP3A4 in the Tibetan populations. Here, we adopted DNA sequencing to investigate the promoter, exons and surrounding introns, and 3'-untranslated region of the CYP3A4 gene in 96 unrelated healthy Tibetan individuals.We identified 20 different CYP3A4 polymorphisms in the Tibetan population, including two novel variants (21824 A>G and 15580 G>C). In addition, we also determined the allele frequencies of CYP3A4*1A and CYP3A4*1H were 82.29% and 28.13%, respectively. CYP3A4*1P and *1G were relatively rare with frequencies of only 1.04% and 0.52%, respectively. Our results provide information on CYP3A4 polymorphisms in Tibetan individuals which may help to optimize pharmacotherapy effectiveness by providing personalized medicine to this ethnic group.

Citing Articles

Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer.

Kasarla S, Garikapati V, Kumar Y, Dodoala S Endocrinol Metab (Seoul). 2022; 37(3):392-407.

PMID: 35654576 PMC: 9262690. DOI: 10.3803/EnM.2021.1349.

References

Boetsch C, Parrott N, Fowler S, Poirier A, Hainzl D, Banken L . Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. Clin Pharmacokinet. 2015; 55(2):237-47. DOI: 10.1007/s40262-015-0312-0. View

Amirimani B, Ning B, Deitz A, Weber B, Kadlubar F, Rebbeck T . Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen. 2003; 42(4):299-305. DOI: 10.1002/em.10199. View

Garsa A, McLeod H, Marsh S . CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005; 6:19. PMC: 1142317. DOI: 10.1186/1471-2350-6-19. View

Eissing T, Lippert J, Willmann S . Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol Diagn Ther. 2012; 16(1):43-53. DOI: 10.2165/11597930-000000000-00000. View

Lakhman S, Ma Q, Morse G . Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics. 2009; 10(8):1323-39. PMC: 2776626. DOI: 10.2217/pgs.09.53. View

Jiang Y, Fan X, Wang Y, Chen P, Zeng H, Tan H . Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration. Toxicol Sci. 2014; 143(1):107-15. PMC: 4334815. DOI: 10.1093/toxsci/kfu216. View

Zuo J, Xia D, Jia L, Guo T . Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie. 2012; 67(7):639-44. View

Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V . Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006; 79(6):570-80. DOI: 10.1016/j.clpt.2006.02.003. View

Fukuyoshi S, Kometani M, Watanabe Y, Hiratsuka M, Yamaotsu N, Hirono S . Molecular Dynamics Simulations to Investigate the Influences of Amino Acid Mutations on Protein Three-Dimensional Structures of Cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62. PLoS One. 2016; 11(4):e0152946. PMC: 4821567. DOI: 10.1371/journal.pone.0152946. View

10.

Lee J, Cheong H, Kim L, Kim J, Seo D, Kim Y . Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. Korean J Physiol Pharmacol. 2014; 17(6):479-84. PMC: 3874433. DOI: 10.4196/kjpp.2013.17.6.479. View

11.

Matsumura K, Saito T, Takahashi Y, Ozeki T, Kiyotani K, Fujieda M . Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol. 2004; 65(2):326-34. DOI: 10.1124/mol.65.2.326. View

12.

Barrett J, Fry B, Maller J, Daly M . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2004; 21(2):263-5. DOI: 10.1093/bioinformatics/bth457. View

13.

Hu Y, He J, Chen G, Wang D, Liu Z, Zhang C . CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta. 2005; 353(1-2):187-92. DOI: 10.1016/j.cccn.2004.11.005. View

14.

Dai D, Tang J, Rose R, Hodgson E, Bienstock R, Mohrenweiser H . Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001; 299(3):825-31. View

15.

Jin M, Gock S, Jannetto P, Jentzen J, Wong S . Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2006; 29(7):590-8. DOI: 10.1093/jat/29.7.590. View

16.

Lamba J, Lin Y, Thummel K, Daly A, Watkins P, Strom S . Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002; 12(2):121-32. DOI: 10.1097/00008571-200203000-00006. View

17.

Cai N, Li B, Huang X, Xu K, Feng H, Cheng Z . A non-invasive CYP3A4 biomarker and body mass index predict cyclosporine dosage requirements in Chinese renal transplant recipients. Pharmazie. 2016; 70(12):815-8. View

18.

Drogemoller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D . Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet. 2013; 4:17. PMC: 3574981. DOI: 10.3389/fgene.2013.00017. View

19.

Georgitsi M, Zukic B, Pavlovic S, Patrinos G . Transcriptional regulation and pharmacogenomics. Pharmacogenomics. 2011; 12(5):655-73. DOI: 10.2217/pgs.10.215. View

20.

ADAMEC C . [EXAMPLE OF THE USE OF THE NONPARAMETRIC TEST. TEST X2 FOR COMPARISON OF 2 INDEPENDENT EXAMPLES]. Cesk Zdrav. 1964; 12:613-9. View